IBIO — iBio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1420720 ·
Last close
$0.75
Market Cap
$52.71M
52W High
$3.82
52W Low
$0.68
ADV30
671,336
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,075,000 | — | -8,338,000 | -7,551,000 | 88,651,000 | 45,435,000 | 10,081,000 |
| Jun 2026 | 0 | — | -6,377,000 | -10,601,000 | 99,110,000 | 56,395,000 | 13,397,000 |
| Mar 2026 | 0 | — | -8,365,000 | -7,730,000 | 85,834,000 | 47,631,000 | 8,297,000 |
| Dec 2025 | 0 | — | -9,445,000 | -8,993,000 | 64,393,000 | 28,672,000 | 7,833,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,940,000
Investing CF
$-10,960,000
Financing CF
$55,224,000
CapEx
$-1,398,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.31
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-372,819,000
Inventory
—
Receivables
$1,249,000
ST Investments
$31,219,000
EBIT TTM
$-34,858,000
Pretax Income TTM
$-34,875,000
Interest Exp TTM
$17,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,075,000
EBITDA
$-31,925,000
Free Cash Flow
$-19,561,000
Enterprise Value
$-23,033,484
Total Cash
$76,654,000
Total Debt
$2,068,000
Shares Out
70,455,809
Trailing EPS
$-0.27
Book Value
$1.22
ROE
-51.8%
ROA
-26.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 100,000 | -30,138,000 | -33,044,000 | 99,110,000 | 13,397,000 | 85,713,000 | -23,218,000 |
| Jun 2025 | 400,000 | -18,602,000 | -18,377,000 | 23,185,000 | 8,305,000 | 14,880,000 | -15,304,000 |
| Jun 2024 | 225,000 | -16,634,000 | -24,907,000 | 28,734,000 | 7,410,000 | 21,324,000 | -18,554,000 |
| Jun 2023 | 0 | -29,343,000 | -65,010,000 | 41,207,000 | 25,826,000 | 15,381,000 | -30,436,000 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$100,000
NetIncome TTM
$-33,044,000
OpCashFlow TTM
—
Assets (Latest)
$85,834,000
Forward EPS
$-0.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | $52.54M | $1.18 | — |
| SPRO | Spero Therapeutics, Inc. | $52.51M | $0.90 | — |
| AZR | Azora Therapeutics, Inc. (DE) | $52.36M | $3.66 | — |
| XLO | Xilio Therapeutics, Inc. | $53.26M | $7.54 | — |
| IBO | IMPACT BIOMEDICAL INC. | $53.31M | $6.17 | — |
News headlines (Yahoo Finance, 1h cache)
iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
2026-11-16 21:30 · Yahoo
iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline
2026-11-12 08:12 · Yahoo
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
2026-11-10 21:30 · Yahoo
iBio to Participate in Upcoming Investor Conferences
2026-11-02 21:30 · Yahoo
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
2026-10-13 11:00 · Yahoo
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
2026-09-01 20:30 · Yahoo
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-08-28 11:00 · Yahoo
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
2026-07-01 11:00 · Yahoo
iBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 20:01 · Yahoo
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.